PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Category:
Sort By:
Feb 07, 2017
Feb 07, 2017

byncaipen

Ophthalmology

St. Marys, West Virginia ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) updates its stockholders on the testing of neuronal retinal cells in living tissue at the University of British Columbia (“UBC”) under the guidance of Dr. Gregory-Evans. As explained by Dr. Gregory-Evans, the research program at UBC will be determining whether AAGP® can...Read more
Jan 24, 2017
St. Marys, West Virginia ProtoKinetix, Incorporated (PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announced that the Governors of the University of Alberta have received a “No Objection Letter” from Health Canada to its Clinical Trial Application entitled: “Clinical Study using Antiaging Glycopeptide (PKX-001) in Islet Transplantation”. This authorization will allow the clinical trial group to...Read more
Jan 17, 2017
St. Marys, West Virginia ST. MARYS, W. Va. — ProtoKinetix, Incorporated (OTC: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) today announced that the Governors of the University of Alberta have submitted an Investigational Testing Authorization application to commence clinical studies in Canada. This authorization will allow the clinical trial group to enroll Canadian patients into the...Read more
Jul 14, 2016
St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB:PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) is pleased to provide the following corporate update to its stockholders:The management team has been very busy since our last update.  The following is a summary of our strategy and action in support of the Company’s direction. Clinical Trial Application progress: Method Development...Read more
Jun 16, 2016
St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB:PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) is pleased to announce that it has raised US $166,000 with the sale of 4,150,000 shares of common stock at US $0.04 per share in the first tranche of a non-brokered private placement (the “Offering”) that closed on June 16, 2016.  ProtoKinetix has...Read more
Jun 07, 2016
St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB:PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix’ AAGP® has been published in the Journal of Tissue Engineering and Regenerative Medicine and is available online at: Anti-ageing glycoprotein promotes long-term survival of transplanted neurosensory precursor cells AAGP®,...Read more
May 12, 2016
St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) is pleased to update its stockholders on the progress that it has made toward the application to conduct clinical trials in Canada with Health Canada. AmbioPharm, Inc. of North Augusta, South Carolina, has completed the first run of Good Manufacturing Practice (GMP)...Read more
May 02, 2016
St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB:PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix’ AAGP® has been accepted by the Journal of Tissue Engineering and Regenerative Medicine for publication. The date of publication is unknown at this time but should be available online...Read more
Apr 26, 2016
St. Marys, West Virginia ProtoKinetix, Incorporated (OTCQB: PKTX) (the “Company” or “ProtoKinetix”) (www.protokinetix.com) outlines the steps to be completed for the application to conduct a clinical trial in Canada. For the last four years ProtoKinetix has been involved in a collaboration with the Laboratory of Dr. James Shapiro, M.D., Ph.D., FRCSC, the director of the...Read more

Subscribe for updates

Get alerts about company news and key findings directly in your inbox.

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.

Picture of a molecule
Picture of a molecule